Pre-CROI HIV Cure Review Workshop Organized by Community Advocates- Meeting Notes
March 8, 2012
Frailty & Muscle Loss Increase Mortality & Are Common in HIV+
March 9, 2012

Fw: Breaking, Clinically Relevant HIV/AIDS Research From CROI 2012

From: “The Body PRO” <>
Date: 08 Mar 2012 14:38:17 -0500
To: <>
ReplyTo: “The Body PRO” <>
Subject: Breaking, Clinically Relevant HIV/AIDS Research From CROI 2012

Welcome to The Body PRO Newsletter, a bi-weekly review of the latest breaking news and research in HIV medicine, aimed specifically at informing health care professionals. covers CROI 2012
The 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) is wrapping up in Seattle, Wash., but’s coverage of this critical meeting is just heating up!

Visit our CROI 2012 home page for a growing selection of articles in which our team recaps and analyzes the clinical significance of a wide array of presented studies. Currently available conference coverage includes:

Much more will be added over the next several days, including the latest on antiretroviral clinical trials, immune-based therapies and a range of HIV-related comorbidities. Be sure to check back often for the latest summaries, analyses and discussions on clinically relevant CROI 2012 research — and follow @MylesatTheBody on Twitter for bite-sized, real-time updates directly from the conference.
Although CROI 2012 is capturing headlines on the research front this week, the world keeps on turning, and there are other developments to report that are of importance to HIV frontline professionals. Here is a sampling of stories recently published on

  • New HIV Care Guidelines Focus on Entry Into and Retention in Care
    In this week’s Annals of Internal Medicine, an expert panel convened by the International Association of Physicians in AIDS Care (IAPAC) published guidelines on entry into care, patient retention and adherence to HIV medications. Ben Young, M.D., Ph.D., examines why we these new guidelines are worth paying attention to.
  • Interactions Between Protease Inhibitors and Statins Can Increase the Risk of Muscle Injury
    A new U.S. Food and Drug Administration warning cautions against drug-drug interactions between statins and protease inhibitors used in the treatment of HIV and hepatitis C. The warning states that the interaction can cause an increase in statin levels that may increase myopathy risk.
  • Tenofovir Linked With Risk of Kidney Damage
    A recent study offers the most conclusive evidence to date that tenofovir (Viread), one of the fundamental backbones of antiretroviral therapy in the U.S., can increase an HIV-infected patient’s risk of kidney damage and chronic renal disease. Despite the findings, the clinical ramifications of the data are unclear.
  • HIV/AIDS Organization Spotlight: Mujeres Unidas
    HIV stigma still runs deep in San Antonio, Texas, where many HIV-infected patients are Latinos. “We’ve got people in doctors’ offices — front offices, back offices — where we’ve had clients that appear for an appointment, and they’re told, ‘Oh, the doctors won’t see patients like you,'” says Tina Sigler, the executive director of Mujeres Unidas.
  • Mapping the Virus With Geographic Information Systems
    A new type of technology may allow frontline HIV professionals and public health officials across the U.S. to develop a more complete understanding for the drivers of HIV in their communities than ever before. It does so by tying basic info about the area (such as education, income levels or even the presence of mass transportation options) into HIV-specific data such as incidence and prevalence.

About This E-Mail This e-mail newsletter was sent to It is provided free of charge to our registered members of The Body PRO. Want to change your subscription? Click here to modify your subscription information online. Missed a newsletter? Our archive of past newsletters will keep you up-to-date. Have any other questions or comments? Feel free to e-mail us at or snail-mail us at: The Body PRO Newsletter
Remedy Health Media, LLC
250 West 57 Street
New York, NY 10107
Nelson Vergel
Nelson Vergel
Chemical engineer, 34+ year HIV and cancer survivor, health author and educator . Founder of , , and

Comments are closed.